"sputnik-v-vaccine"

Trial will be a multicentre, randomised controlled study, which will include safety and immunogenicity

The vaccine supplies for the global market will be produced by RDIF's international partners in India, Brazil, China, South Korea and other countries.

The confirmation is based on the first interim data from the largest randomised, placebo-controlled Phase-III clinical trials in Russia involving 40,000 volunteers

Collaboration will allow Dr Reddy’s to identify and use some of the Biotechnology Industry Research Assistance Council’s clinical trial centres